Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.02. | C4 Therapeutics GAAP EPS of -$0.49 beats by $0.02, revenue of $5.2M beats by $0.77M | 4 | Seeking Alpha | ||
27.02. | C4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 200 | GlobeNewswire (Europe) | Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial... ► Artikel lesen | |
27.02. | C4 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
27.02. | C4 Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
27.02. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
18.02. | C4 Therapeutics Vorstand Scott Boyle verkauft Aktien im Wert von 3.650 US-Dollar | 2 | Investing.com Deutsch | ||
14.01. | C4 Therapeutics gains after portfolio updates | 2 | Seeking Alpha | ||
14.01. | C4 Therapeutics macht Fortschritte bei wichtigen klinischen Studien für 2025 | 4 | Investing.com Deutsch | ||
14.01. | C4 Therapeutics, Inc.: C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology | 137 | GlobeNewswire (Europe) | Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's... ► Artikel lesen | |
14.01. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
08.01. | Equities Analysts Issue Forecasts for C4 Therapeutics FY2029 Earnings | 2 | MarketBeat | ||
20.12.24 | C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts | 5 | MarketBeat | ||
09.12.24 | Aktien von C4 Therapeutics steigen nach positiven frühen Krebsstudienergebnissen | 6 | Investing.com Deutsch | ||
09.12.24 | C4 Therapeutics stock surges on positive early cancer trial results | 2 | Investing.com | ||
09.12.24 | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.12.24 | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader | 127 | GlobeNewswire (Europe) | In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR)... ► Artikel lesen | |
20.11.24 | C4 Therapeutics beruft Steve Hoerter in den Vorstand | 2 | Investing.com Deutsch | ||
20.11.24 | C4 Therapeutics appoints Steve Hoerter to board | 1 | Investing.com | ||
20.11.24 | C4 Therapeutics, Inc.: C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors | 1 | GlobeNewswire (USA) | ||
20.11.24 | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 36,200 | -1,92 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
EVOTEC | 5,900 | -0,08 % | RBC stuft Evotec auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Evotec mit einem Kursziel von 11,60 Euro auf "Outperform" belassen. Nach 15 sehr turbulenten Monaten dürfte der nächste wichtige... ► Artikel lesen | |
TEMPUS AI | 46,220 | 0,00 % | Tempus AI, Inc. (NASDAQ:TEM) Sees Significant Increase in Short Interest | ||
BIONTECH | 83,65 | -1,82 % | Lululemon | Ubisoft | Steyr - Curevac mit erstem Erfolg gegen Biontech | Markus Weingran - Mein Tipp: SMARTBROKER+: https://broker-tipp.de/ (Werbung) Willkommen bei der Börsenlounge mit Markus Weingran. Die Themen heute: Lululemon | Ubisoft | Steyr - Curevac mit erstem Erfolg... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,600 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 43,110 | -7,33 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
BEAM THERAPEUTICS | 16,425 | 0,00 % | Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard | ||
AVIDITY BIOSCIENCES | 28,120 | -5,54 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 16,180 | -2,53 % | Arcutis Biotherapeutics, Inc.: Arcutis and Padagis Agree to Stay Patent Lawsuit | WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
OSR HOLDINGS | 2,430 | 0,00 % | OSR Holdings Inc.: OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate ... | SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies... ► Artikel lesen | |
BB BIOTECH | 30,450 | -2,87 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,800 | 0,00 % | Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March | ||
CG ONCOLOGY | 18,750 | -16,41 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
ADMA BIOLOGICS | 19,470 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
ARS PHARMACEUTICALS | 13,415 | +2,80 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen |